A Study of Overall Survival in Participants With Metastatic Colorectal Cancer (mCRC)

Inclusion Criteria: * Metastatic Colorectal Cancer (CRC) participants in the Flatiron database as defined by: * Diagnosed with CRC (ICD-9 153.x or 154.x or ICD-10 C18x, or C19x, or C20x, or C21x) * Pathology consistent with CRC * At least two documented clinical visits on or after January 1, 2013 * Evidence of Stage IV or recurrent metastatic CRC diagnosed on or after January 1, 2013 * Participants with high levels of microsatellite instability (MSI-H) and/or mismatch repair (MMR) protein deficiency (dMMR) * Participants who received 2L therapy of interest on or after the initial mCRC diagnosis date * Participants who had at least 1 month medical data during the prior to and post periods; however, participants who died within 1 month after the index date will not be excluded from the study Exclusion Criteria: * Participants \<18 years of age at index date * Participants who received clinical trial drug during the prior or post periods